Literature DB >> 24133598

Clinicopathological features of acute promyelocytic leukemia: an experience in one institute emphasizing the morphological and immunophenotypic changes at the time of relapse.

Miyuki Yoshii1, Mitsuaki Ishida, Takashi Yoshida, Hiroko Okuno, Ryota Nakanishi, Akiko Horinouchi, Keiko Hodohara, Hidetoshi Okabe.   

Abstract

Acute promyelocytic leukemia (APL) has two morphological variants, namely macrogranular (M3) and microgranular (M3v). M3v, characterized by the presence of neoplastic promyelocytes with only sparse fine azurophilic granules, accounts for 10-25% of all APL and has unique biological characteristics. Relapse occurs in approximately 20% of patients with APL. The morphological type of the leukemic cells at relapse is usually identical with the primary disease, and only one case of morphological change at relapse has been reported. Here, we analyzed the clinicopathological features of APL, including 4 relapsed cases emphasizing morphological changes at the time of relapse. The unique finding of the present study is that 2 of 4 relapsed cases changed from M3 to M3v at relapse. The morphological features of these were different in each case (one had blastic features and the other resembled monocytoid leukemic cells). Cytogenetic analyses revealed the continued presence of t(15;17)(q22;q12) at the time of relapse and morphological change. Moreover, the immune phenotype of the leukemic cells changed from CD2(-)/CD34(-) to CD2(+)/CD34(+) at that time. These findings suggest that morphological change at relapse in APL may not be a rare event, and that the leukemic cells can show variable morphological features at the time of relapse, which could result in misdiagnosis as a different type of acute myeloid leukemia. Therefore, a comprehensive approach with emphasis on combined morphological, immunophenotypic, and cytogenetic analyses is important for diagnosis and appropriate treatment of relapsed APL.

Entities:  

Keywords:  Acute promyelocytic leukemia; macrogranular variant; microgranular variant; relapse

Mesh:

Year:  2013        PMID: 24133598      PMCID: PMC3796242     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  10 in total

1.  CD34-positive acute promyelocytic leukemia is associated with leukocytosis, microgranular/hypogranular morphology, expression of CD2 and bcr3 isoform.

Authors:  R Foley; P Soamboonsrup; R F Carter; A Benger; R Meyer; I Walker; Y Wan; W Patterson; A Orzel; L Sunisloe; B Leber; P B Neame
Journal:  Am J Hematol       Date:  2001-05       Impact factor: 10.047

2.  Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic Acid and anthracycline-based chemotherapy.

Authors:  Pau Montesinos; José D González; José González; Chelo Rayón; Elena de Lisa; Maria L Amigo; Gert J Ossenkoppele; María J Peñarrubia; Manuel Pérez-Encinas; Juan Bergua; Guillermo Debén; María J Sayas; Javier de la Serna; Josep M Ribera; Javier Bueno; Gustavo Milone; Concha Rivas; Salut Brunet; Bob Löwenberg; Miguel Sanz
Journal:  J Clin Oncol       Date:  2010-07-12       Impact factor: 44.544

3.  Morphology of acute promyelocytic leukemia with cytogenetic or molecular evidence for the diagnosis: characterization of additional microgranular variants.

Authors:  P B Neame; P Soamboonsrup; B Leber; R F Carter; L Sunisloe; W Patterson; A Orzel; S Bates; J A McBride
Journal:  Am J Hematol       Date:  1997-11       Impact factor: 10.047

4.  Clinical and genetic features of therapy-related myeloid neoplasms after chemotherapy for acute promyelocytic leukemia.

Authors:  Jun Imagawa; Yuka Harada; Takeshi Shimomura; Hideo Tanaka; Yoshiko Okikawa; Hideo Hyodo; Akiro Kimura; Hironori Harada
Journal:  Blood       Date:  2010-09-22       Impact factor: 22.113

5.  Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group.

Authors:  Martin S Tallman; Haesook T Kim; Pau Montesinos; Frederick R Appelbaum; Javier de la Serna; John M Bennett; Guillermo Deben; Clara D Bloomfield; Jose Gonzalez; James H Feusner; Marcos Gonzalez; Robert Gallagher; Jose D Gonzalez-San Miguel; Richard A Larson; Gustavo Milone; Elisabeth Paietta; Chelo Rayon; Jacob M Rowe; Concha Rivas; Charles A Schiffer; Edo Vellenga; Lois Shepherd; James L Slack; Peter H Wiernik; Cheryl L Willman; Miguel A Sanz
Journal:  Blood       Date:  2010-09-21       Impact factor: 22.113

6.  Acute promyelocytic leukemia at time of relapse commonly demonstrates cytogenetic evidence of clonal evolution and variability in blast immunophenotypic features.

Authors:  Nikolay D Dimov; L Jeffrey Medeiros; Farhad Ravandi; Carlos E Bueso-Ramos
Journal:  Am J Clin Pathol       Date:  2010-03       Impact factor: 2.493

7.  Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups.

Authors:  M A Sanz; F Lo Coco; G Martín; G Avvisati; C Rayón; T Barbui; J Díaz-Mediavilla; G Fioritoni; J D González; V Liso; J Esteve; F Ferrara; P Bolufer; C Bernasconi; M Gonzalez; F Rodeghiero; D Colomer; M C Petti; J M Ribera; F Mandelli
Journal:  Blood       Date:  2000-08-15       Impact factor: 22.113

8.  A surrogate marker profile for PML/RAR alpha expressing acute promyelocytic leukemia and the association of immunophenotypic markers with morphologic and molecular subtypes.

Authors:  E Paietta; O Goloubeva; D Neuberg; J M Bennett; R Gallagher; J Racevskis; G Dewald; P H Wiernik; M S Tallman
Journal:  Cytometry B Clin Cytom       Date:  2004-05       Impact factor: 3.058

9.  Ultrastructural characteristics and lysozyme content in hypergranular and variant type of acute promyelocytic leukaemia.

Authors:  D Shaft; M Shtalrid; A Berebi; D Catovsky; P Resnitzky
Journal:  Br J Haematol       Date:  1998-12       Impact factor: 6.998

10.  Expression of CD2 in acute promyelocytic leukemia correlates with short form of PML-RARalpha transcripts and poorer prognosis.

Authors:  Pei Lin; Suyang Hao; L Jeffrey Medeiros; Elihu H Estey; Sherry A Pierce; Xuemei Wang; Armand B Glassman; Carlos Bueso-Ramos; Yang O Huh
Journal:  Am J Clin Pathol       Date:  2004-03       Impact factor: 2.493

  10 in total
  4 in total

1.  Microgranular variant of acute promyelocytic leukemia with der(17) ins(17;15): A case report and review of the literature.

Authors:  Hongzai Guan; Jing Liu; Xiaofang Guo; Chunmei Wu; Huawei Yu
Journal:  Exp Ther Med       Date:  2015-06-18       Impact factor: 2.447

2.  Molecular and hematologic relapses in adult patients with acute promyelocytic leukemia: a cohort study.

Authors:  Ilana de França Azevedo; Michelline Gomes Magalhães; Fernanda Ribeiro Souto; Washington Batista das Neves; Fárida Coeli de Barros Correia Melo; Eduardo Magalhães Rego; Raul Antônio Morais Melo
Journal:  Rev Bras Hematol Hemoter       Date:  2016-10-21

3.  Acute promyelocytic leukemia in a long-standing HIV-positive patient: Case report and literature review.

Authors:  Daniela P Mendes-de-Almeida; Teresa de Souza Fernandez; Viviane Lamim Lovatel; Moises Martins da Rocha; Bernadete Evangelho Gomes; Bárbara C R Monte-Mór; Danielle Tavares Vianna; Marília T G Alcoforado; João Marcello P B Kronemberg; João Pedro S C Cardoso; Vanessa da Gama Oliveira; Joanna Bokel; Alexandre G Vizzoni; Estevão Portela Nunes; Beatriz Grinsztejn
Journal:  Leuk Res Rep       Date:  2022-07-26

4.  Flow cytometric analysis of CD64 expression pattern and density in the diagnosis of acute promyelocytic leukemia: a multi-center study in Shanghai, China.

Authors:  Min Liu; Xiangqin Weng; Shenglan Gong; Hui Chen; Jing Ding; Mengqiao Guo; Xiaoxia Hu; Jianmin Wang; Jianmin Yang; Gusheng Tang
Journal:  Oncotarget       Date:  2017-09-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.